News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,431 Results
Type
Article (135)
Press Release (1296)
Section
Business (598)
Career Advice (1)
Deals (89)
Drug Development (298)
FDA (34)
Job Trends (61)
News (989)
Policy (60)
Tag
Academia (3)
Alliances (213)
Alzheimer's disease (1)
Antibody-drug conjugate (ADC) (1)
Approvals (33)
Artificial intelligence (1)
Autoimmune disease (2)
Best Places to Work (53)
Brain cancer (2)
Cancer (20)
Career advice (1)
CAR-T (3)
Cell therapy (5)
Clinical research (259)
Collaboration (6)
COVID-19 (1)
C-suite (7)
Data (13)
Diagnostics (4)
Drug discovery (1)
Earnings (252)
Events (194)
Executive appointments (3)
FDA (35)
Funding (3)
Gene editing (2)
GLP-1 (13)
Government (3)
Healthcare (12)
Infectious disease (1)
IPO (48)
Job creations (10)
Job search strategy (1)
Kidney cancer (2)
Layoffs (1)
Legal (16)
Lung cancer (1)
Lymphoma (9)
Medical device (3)
Medtech (3)
Mergers & acquisitions (43)
Multiple sclerosis (1)
Neuroscience (3)
NextGen: Class of 2026 (10)
Non-profit (4)
Pancreatic cancer (1)
People (135)
Phase 1 (87)
Phase 2 (100)
Phase 3 (98)
Pipeline (20)
Postmarket research (4)
Preclinical (30)
Radiopharmaceuticals (2)
Rare diseases (2)
Real estate (10)
Regulatory (43)
Research institute (2)
Spinal muscular atrophy (3)
Startups (11)
Supply chain (4)
Date
Last 30 days (6)
Last 365 days (49)
2026 (8)
2025 (46)
2024 (61)
2023 (85)
2022 (108)
2021 (143)
2020 (165)
2019 (90)
2018 (99)
2017 (106)
2016 (53)
2015 (85)
2014 (70)
2013 (53)
2012 (52)
2011 (81)
2010 (56)
Location
Asia (34)
Australia (6)
California (21)
Canada (4)
Colorado (1)
Europe (625)
Illinois (1)
Kentucky (1)
Maryland (1)
Massachusetts (27)
New Jersey (2)
New York (9)
North Carolina (2)
Northern California (20)
South America (1)
Southern California (1)
United States (62)
1,431 Results for "servier".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Servier’s Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
December 8, 2025
·
2 min read
Press Releases
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
January 5, 2026
·
3 min read
Press Releases
Servier’s New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research
November 7, 2025
·
10 min read
Press Releases
Servier’s Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
November 11, 2025
·
9 min read
Neuroscience
Servier Bets $450M On Kaerus’ Fragile X Syndrome Therapy
KER-0193 is a modulator of ion channels connected to autism spectrum disorder. The FDA bestowed orphan drug and rare pediatric drug designations on the candidate earlier this year.
September 8, 2025
·
2 min read
·
Tristan Manalac
Cancer
Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA
The French giant is gaining access to darovasertib, a small molecule protein kinase C inhibitor already in Phase II/III trials, with rights for the whole world besides the U.S.
September 2, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
September 2, 2025
·
8 min read
Press Releases
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
November 4, 2025
·
12 min read
Press Releases
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
September 8, 2025
·
6 min read
Press Releases
Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
July 28, 2025
·
11 min read
1 of 144
Next
